Thinking and memory in long-term survivors of lymphoma
Checks thinking and memory in adults who were treated for lymphoma.
Plain-language title generated from the registry record
Registry title: Neurocognitive Assessment in Long-Term Survivors of Lymphoma
Key facts
- Where
- Ancona, Aviano, Bari, Legnano, Milan, and Palermo, ItalySee the 7 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 55 years old?
Source: NCT07652476, who can take part
Where in Italy
- Clinica di Ematologia, AOU Ospedali RiunitiAncona, ItalyNo longer taking part
- Divisione di Oncologia e dei Tumori immuno-correlati - IRCCS Centro di Riferimento Oncologico di AvianoAviano, ItalyNo longer taking part
- U.O.C Ematologia - IRCCS Istituto Tumori Giovanni Paolo IIBari, ItalyNo longer taking part
- U.O.C. Ematologia Ospedale Civile di Legnano - ASST Ovest MilaneseLegnano, ItalyNo longer taking part
- Ematologia - Ospedale Maggiore Policlinico - Fondazione IRCCS Ca GrandaMilan, ItalyNo longer taking part
- SC Ematologia - ASST Grande Ospedale Metropolitano NiguardaMilan, ItalyNo longer taking part
- Ematologia AOU Policlinico GiacconePalermo, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fondazione Italiana Linfomi - ETS
- Trial code
- NCT07652476
- Record updated
- 22 June 2026
- Original description
This is an observational, multicenter, prospective cohort study including patients treated for lymphoma in Italian real-life. Patients eligible for the enrollment in the study will be consecutively included in Italian FIL centers. Patients will be evaluated once during regular follow-up, in the absence of clinical or radiologic signs of disease relapse.Read full original descriptionShow less
Neurocognitive Assessment in Long-Term Survivors of Lymphoma: An Observational Study by the Fondazione Italiana Linfomi (FIL)
This is an observational, multicenter, prospective cohort study including patients treated for lymphoma in Italian real-life. Patients eligible for the enrollment in the study will be consecutively included in Italian FIL centers. Patients will be evaluated once during regular follow-up, in the absence of clinical or radiologic signs of disease relapse.
The assessment of neurocognitive functioning will be performed through a panel of tests, both self-administered and individually administered (about 1 hour). The administration of these neuropsychological tests should be done according to a standardized and predefined order. If available, according to local practice, a neuropsychologist may be involved in test administration and in the evaluation of the results.
Based on its observational nature, no treatment change or modification or additional exams or visits will be required because of being enrolled in this study.
Inclusion: Patients with previous diagnosis of classic Hodgkin Lymphoma (cHL) or Diffuse Large B Cell Lymphoma (DLBCL) or Primary Mediastinal B Cell Lymphoma (PMBCL); Patients in complete remission after first line anthracycline containing regimen (ABVD, BV-AVD, BEACOPP, R-CHOP, Pola-R-CHP o R-DA-EPOCH) +/- radiotherapy; Age ≥ 25 and ≤ 55 at enrollment; Patients between third and fifth year of follow-up after the end of the first line treatment; Absence of signs or symptoms of disease relapse.
Exclusion: Patients that received brain/neuroaxis radiotherapy; Patients with CNS disease localization; Pre-existing severe psychiatric or neurologic comorbidities influencing neurocognitive assessment.